HPV Vaccination and Screening Timing
HPV vaccination should be routinely initiated between ages 9-12 years, with catch-up vaccination through age 26 years, while cervical cancer screening should begin at age 25 years using primary HPV testing every 5 years through age 65 years.
HPV Vaccination Timing
Routine Vaccination (Ages 9-12 Years)
The optimal window for HPV vaccination is ages 9-12 years, with providers encouraged to start offering the vaccine as early as age 9 or 10 years 1. This early initiation achieves several critical goals:
- Higher completion rates when started earlier in the recommended age range
- Stronger immune response at younger ages with no evidence of waning protection
- Flexibility for providers to spread vaccines across multiple visits rather than administering 3+ vaccines simultaneously at age 11-12
- Removes association with sexual activity discussions, potentially reducing parental hesitancy
Dosing schedule: Children who initiate the series at ages 9-14 years require only 2 doses (given 6-12 months apart), while those starting at age 15 or older need 3 doses 2.
Catch-Up Vaccination (Through Age 26 Years)
All persons through age 26 years who are not adequately vaccinated should receive catch-up vaccination 1. However, providers should counsel individuals aged 22-26 years that vaccination at older ages is less effective in lowering cancer risk due to likely prior HPV exposure.
Vaccination Beyond Age 26 Years
The ACS explicitly does not recommend catch-up vaccination for adults older than 26 years 1. The guideline specifically rejects shared clinical decision-making for ages 27-45 years due to:
- Low effectiveness and minimal cancer prevention potential in this age group
- Burden of decision-making on patients and clinicians
- Lack of sufficient guidance on selecting individuals who might benefit
- Prior HPV exposure significantly reduces vaccine effectiveness 3
HPV Screening Timing
Screening Initiation (Age 25 Years)
Cervical cancer screening should begin at age 25 years, not earlier 4. This represents a change from previous recommendations that started screening at age 21 years.
Screening Method and Interval (Ages 25-65 Years)
Primary HPV testing every 5 years is the preferred strategy 4. The screening approach follows this hierarchy:
- Preferred: Primary HPV testing every 5 years
- Acceptable (if primary HPV testing unavailable):
- Co-testing (HPV + cytology) every 5 years, OR
- Cytology alone every 3 years
The screening assay should differentiate HPV genotypes 16 and 18 while detecting other high-risk types, using clinically validated tests 5, 6.
Screening Cessation (Age 65+ Years)
Discontinue all cervical cancer screening after age 65 years if the individual meets both criteria 4:
- No history of cervical intraepithelial neoplasia grade 2 or worse within the past 25 years
- Documented adequate negative prior screening in the prior 10 years
Key Clinical Pitfalls to Avoid
- Do not screen before age 25 years, even in vaccinated individuals—screening recommendations do not change based on vaccination status 4
- Do not offer vaccination beyond age 26 years as routine practice; the evidence does not support population-level benefit 1, 3
- Do not continue screening after age 65 years in adequately screened individuals with negative results
- Do not use cytology alone as first-line screening when primary HPV testing is available—this is a transitional recommendation only 4
Impact on Cancer Prevention
This combined vaccination and screening strategy is projected to prevent 92% of HPV-attributable cancers (approximately 32,100 cases annually in the US) and achieve cervical cancer elimination by 2030-2037 1, 7.